title: Induction of tolerance to islet xenografts in a concordant rat-to-mouse model.
abstract: Induction of tolerance to concordant rat islet xenografts (150 Wistar-Furth [WF] islets) in streptozocin-induced (STZ) diabetic mice (C57BL/6) was determined at three different sites for islet implantation (thymus, kidney capsule, and liver). Islets transplanted into the thymus or kidney capsule were either fresh or cultured at 24 degrees C for 7 days, and the mice received a single injection of either anti-mouse lymphocyte serum (MALS) alone or anti-rat lymphocyte serum (RALS) and MALS. Islets transplanted into the liver via the portal vein were cultured at 24 degrees C for 7 days, and the mice received a single injection of MALS and RALS. To document the induction of tolerance, recipients with islet xenografts surviving > 100 days were made diabetic again by STZ (thymus and liver) or nephrectomy (kidney capsule) and received a second transplant of 150 fresh WF islets in the kidney capsule. Kidney capsule placement of fresh or cultured islets with MALS alone or MALS and RALS did not induce tolerance in a significant number of recipients. The intrathymic transplantation of fresh or cultured islets with MALS alone resulted in prolonged WF islet xenograft survival (mean survival time of 39.7 +/- 7.9 days) but did not result in tolerance, whereas the administration of MALS and RALS with the intrathymic placement of fresh or cultured islets induced tolerance in approximately 50% of the mice. Intrahepatic transplantation of cultured islets with MALS and RALS resulted in tolerance to donor islets in 90% of the recipients. Donor specificity was evaluated by a third major histocompatibility complex-disparate fresh Lewis islet xenograft.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110.
authors.forename: J A
authors.initials: JA
authors.lastname: Goss
authors.forename: Y
authors.initials: Y
authors.lastname: Nakafusa
authors.forename: E H
authors.initials: EH
authors.lastname: Finke
authors.forename: M W
authors.initials: MW
authors.lastname: Flye
authors.forename: P E
authors.initials: PE
authors.lastname: Lacy
mesh_terms: D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000628:therapy*; D006085:Graft Survival / Q000276:immunology*; D007165:Immunosuppression Therapy / Q000379:methods*; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D007668:Kidney; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011169:Portal Vein; D051381:Rats; D011917:Rats, Inbred Lew; D011920:Rats, Inbred WF; D013950:Thymus Gland; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology*; D016042:Transplantation, Heterotopic
chemical_list: D000961:Antilymphocyte Serum